Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 41

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib

Brieghel, Christian, Aarup, Kathrine, Torp, Mathias H., Andersen, Michael A., Yde, Christina W., Tian, Xin, Wiestner, Adrian, Ahn, Inhye E., Niemann, Carsten U.·2021·Clinical Cancer Research

Published version of a preprint

Abstract

Purpose: TP53 aberration (TP53 mutation and/or 17p deletion) is the most important predictive marker in chronic lymphocytic leukemia (CLL). Although each TP53 aberration is considered an equal prognosticator, the prognostic value of carrying isolated (single-hit) or multiple (multi-hit) TP53 aberrations remains unclear, particularly in the context of targeted agents. Patients and Methods: We performed deep sequencing of TP53 using baseline samples collected from 51 TP53 aberrant patients treated with ibrutinib in a phase II study (NCT01500733). Results: We identified TP53 mutations in 43 patients (84%) and del(17p) in 47 (92%); 9 and 42 patients carried single-hit and multi-hit TP53, respectively. The multi-hit TP53 subgroup was enriched with younger patients who had prior treatments and unmutated immunoglobulin heavy-chain variable region gene status. We observed significantly shorter overall survival, progression-free survival (PFS), and time-to-progression (TTP) in patients with multi-hit TP53 compared with those with single-hit TP53. Clinical outcomes were similar in patient subgroups stratified by 2 or >2 TP53 aberrations. In multivariable analyses, multi-hit TP53 CLL was independently associated with inferior PFS and TTP. In sensitivity analyses, excluding mutations below 1% VAF demonstrated similar outcome. Results were validated in an independent population-based cohort of 112 patients with CLL treated with ibrutinib. Conclusions: In this study, single-hit TP53 defines a distinct subgroup of patients with an excellent long-term response to single-agent ibrutinib, whereas multi-hit TP53 is independently associated with shorter PFS. These results warrant further investigations on prognostication and management of multi-hit TP53 CLL. See related commentary by Bomben et al., p. 4462

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-4890

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 43

  1. Kandoth, 2013, Mutational landscape and significance across 12 major cancer types, Nature, 502, 333, 10.1038/nature12634 · DOI · Paper page
  2. Donehower, 2019, Integrated analysis of TP53 gene and pathway alterations in the Cancer Genome Atlas, Cell Rep, 28, 3010, 10.1016/j.celrep.2019.08.061 · DOI · Paper page
  3. Stilgenbauer, 2014, Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial, Blood, 123, 3247, 10.1182/blood-2014-01-546150 · DOI · Paper page
  4. Bahlo, 2016, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, 17, 779, 10.1016/S1470-2045(16)30029-8 · DOI · Paper page
  5. Burger, 2020, Treatment of chronic lymphocytic leukemia, N Engl J Med, 383, 460, 10.1056/NEJMra1908213 · DOI · Paper page
  6. da Cunha-Bang, 2016, The Danish national chronic lymphocytic leukemia registry, Clin Epidemiol, 8, 561, 10.2147/CLEP.S99486 · doi:10.2147/clep.s99486
  7. Dohner, 2000, Genomic aberrations and survival in chronic lymphocytic leukemia, N Engl J Med, 343, 1910, 10.1056/NEJM200012283432602 · DOI · Paper page
  8. Zenz, 2012, Risk categories and refractory CLL in the era of chemoimmunotherapy, Blood, 119, 4101, 10.1182/blood-2011-11-312421 · doi:10.1182/blood-2011-11-312421
  9. Hallek, 2018, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, 131, 2745, 10.1182/blood-2017-09-806398 · DOI · Paper page
  10. Malcikova, 2018, ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation, Leukemia, 32, 1070, 10.1038/s41375-017-0007-7 · DOI · Paper page
  11. Eichhorst, 2021, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 32, 23, 10.1016/j.annonc.2020.09.019 · DOI · Paper page
  12. Knudson, 1971, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  13. Malcikova, 2009, Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage, Blood, 114, 5307, 10.1182/blood-2009-07-234708 · DOI · Paper page
  14. Zenz, 2010, TP53 mutation and survival in chronic lymphocytic leukemia, J Clin Oncol, 28, 4473, 10.1200/JCO.2009.27.8762 · DOI · Paper page
  15. Stengel, 2017, The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS, and CLL: an analysis of 3307 cases, Leukemia, 31, 705, 10.1038/leu.2016.263 · DOI · Paper page
  16. Campo, 2018, TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics, Haematologica, 103, 1956, 10.3324/haematol.2018.187583 · DOI · Paper page
  17. Nadeu, 2016, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood, 127, 2122, 10.1182/blood-2015-07-659144 · DOI · Paper page
  18. DiNardo, 2020, Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML, Blood, 135, 791, 10.1182/blood.2019003988 · DOI · Paper page
  19. Yu, 2017, Survival of Del17p CLL depends on genomic complexity and somatic mutation, Clin Cancer Res, 23, 735, 10.1158/1078-0432.CCR-16-0594 · DOI
  20. Blakemore, 2020, Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial, Leukemia, 34, 1760, 10.1038/s41375-020-0723-2 · DOI
  21. Brieghel, 2019, Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment, Haematologica, 104, 789, 10.3324/haematol.2018.195818 · DOI
  22. Rossi, 2009, The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness, Clin Cancer Res, 15, 995, 10.1158/1078-0432.CCR-08-1630 · DOI · Paper page
  23. Rossi, 2014, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, 123, 2139, 10.1182/blood-2013-11-539726 · DOI · Paper page
  24. Tam, 2009, De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M.D. Anderson and Mayo Clinic experience, Blood, 114, 957, 10.1182/blood-2009-03-210591 · doi:10.1182/blood-2009-03-210591
  25. Farooqui, 2015, Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial, Lancet Oncol, 16, 169, 10.1016/S1470-2045(14)71182-9 · DOI · Paper page
  26. Byrd, 2019, Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs. ofatumumab, Blood, 133, 2031, 10.1182/blood-2018-08-870238 · DOI · Paper page
  27. O'Brien, 2018, Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience, Blood, 131, 1910, 10.1182/blood-2017-10-810044 · DOI · Paper page
  28. Ahn, 2020, Ibrutinib for chronic lymphocytic leukemia with TP53 alterations, N Engl J Med, 383, 498, 10.1056/NEJMc2005943 · DOI
  29. Aarup, 2020, Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib, Eur J Haematol, 105, 646, 10.1111/ejh.13499 · DOI
  30. Firth, 1993, Bias reduction of maximum likelihood estimates, Biometrika, 80, 27, 10.1093/biomet/80.1.27 · DOI · Paper page
  31. R Core Team, 2020, R: a language and environment for statistical computing
  32. O'Brien, 2018, Prognostic factors for complete response to ibrutinib in patients with chronic lymphocytic leukemia: a pooled analysis of 2 clinical trials, JAMA Oncol, 4, 712, 10.1001/jamaoncol.2017.5604 · DOI
  33. Soumerai, 2019, Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations, Lancet Haematol, 6, e366, 10.1016/S2352-3026(19)30085-7 · DOI
  34. Ahn, 2021, Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model, J Clin Oncol, 39, 576, 10.1200/JCO.20.00979 · DOI
  35. Bieging, 2014, Unravelling mechanisms of p53-mediated tumour suppression, Nat Rev Cancer, 14, 359, 10.1038/nrc3711 · DOI · Paper page
  36. Malcikova, 2015, Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia, Leukemia, 29, 877, 10.1038/leu.2014.297 · DOI
  37. Leeksma, 2021, Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study, Haematologica, 106, 87, 10.3324/haematol.2019.239947 · DOI
  38. European Research Initiative on CLL, Projects: Multicenter study on prognostic and predictive impact of TP53 variants below 10% VAF
  39. Jain, 2019, Ibrutinib and venetoclax for first-line treatment of CLL, N Engl J Med, 380, 2095, 10.1056/NEJMoa1900574 · DOI · Paper page
  40. Hillmen, 2019, Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study, J Clin Oncol, 37, 2722, 10.1200/JCO.19.00894 · DOI · Paper page
  41. Turtle, 2017, Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib, J Clin Oncol, 35, 3010, 10.1200/JCO.2017.72.8519 · DOI · Paper page
  42. Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 · DOI · Paper page
  43. Rogers, 2020, Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia, J Clin Oncol, 38, 3626, 10.1200/JCO.20.00491 · DOI

Cited by

See all 41

Metadata

Authors
Brieghel, C., Aarup, K., Torp, M. H., Andersen, M. A., Yde, C. W., Tian, X., Wiestner, A., Ahn, I. E., & Niemann, C. U.
Affiliations
  • 1Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • 2Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • 3Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • 4Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Venue
Clinical Cancer Research
Published
2021-05-07
Volume
27
Issue
16
Pages
4531-4538
ISSN
  • 1078-0432
  • 1557-3265
Cited by
41
References
6
Language
en
Funders
  • Danish Cancer Society
  • Intramural Research Program of the National Heart, Lung, and Blood Institute
  • Novo Nordisk Foundation (NNF16OC0019302)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-4890
The paper
Brieghel, C., Aarup, K., Torp, M. H., Andersen, M. A., Yde, C. W., Tian, X., Wiestner, A., Ahn, I. E., & Niemann, C. U. (2021). Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-4890

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.